Previous research showed that a low dose of anti-VEGF therapy resulted in vascular normalization and improved antitumor immunity, while a high dose induced hypoxia and an immunosuppressive tumor microenvironment [11, 27, 28]. This evidence concerns the gene VEGFA and neoplasm.